Recent guidelines supported by multiple organizations including the Collage of American Pathologists (CAP) and the National Comprehensive Cancer Network (NCCN) have recommended the universal testing of all newly diagnosed CRC cases for deficient MMR or MSI in order to identify LS associated CRC cases [16, 17]. This evidence concerns the gene MRC1 and colorectal carcinoma.